Trinity Biotech plc (TRIB)
NASDAQ: TRIB · Real-Time Price · USD
0.9402
-0.0049 (-0.52%)
At close: Nov 10, 2025, 4:00 PM EST
0.9580
+0.0178 (1.89%)
After-hours: Nov 10, 2025, 7:15 PM EST
Trinity Biotech Revenue
In the year 2024, Trinity Biotech had annual revenue of $61.56M with 8.31% growth. Trinity Biotech had revenue of $15.86M in the quarter ending December 31, 2024.
Revenue (ttm)
$61.56M
Revenue Growth
+8.31%
P/S Ratio
0.27
Revenue / Employee
$153,504
Employees
401
Market Cap
17.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61.56M | 4.72M | 8.31% |
| Dec 31, 2023 | 56.83M | -5.69M | -9.10% |
| Dec 31, 2022 | 62.52M | -18.63M | -22.96% |
| Dec 31, 2021 | 81.15M | -20.83M | -20.43% |
| Dec 31, 2020 | 101.98M | 11.55M | 12.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TRIB News
- 14 days ago - Trinity Biotech Welcomes Perceptive Advisor's Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth - GlobeNewsWire
- 2 months ago - Trinity Biotech Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - Trinity Biotech Appoints Paul Tivnan as Non-Executive Director - GlobeNewsWire
- 2 months ago - Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation - GlobeNewsWire
- 3 months ago - Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service - GlobeNewsWire
- 3 months ago - Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor - GlobeNewsWire
- 3 months ago - Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service - GlobeNewsWire
- 3 months ago - Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market - GlobeNewsWire